Loading...

Zhu, Viola Weijia

TitleAssistant Health Sciences Professor
InstitutionUniversity of California, Irvine
DepartmentMedicine
Address1001 Health Sciences Road
CA 92697-3950
Phone(714) 456-5153
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Drilon A, Ou SI, Cho BC, Kim DW, Lee J, Lin JJ, Zhu V, Ahn MJ, Camidge DR, Nguyen J, Zhai D, Deng W, Huang Z, Rogers E, Liu J, Whitten J, Lim JK, Stopatschinskaja S, Hyman DM, Doebele RC, Cui JJ, Shaw AT. Repotrectinib (TPX-0005) is a next generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent front mutations. Cancer Discov. 2018 Aug 09. PMID: 30093503.
      View in: PubMed
    2. Lin JJ, Zhu V, Schoenfeld AJ, Yeap BY, Saxena A, Ferris LA, Dagogo-Jack I, Farago AF, Taber A, Traynor A, Menon S, Gainor JF, Lennerz JK, Plodkowski AJ, Digumarthy SR, Ignatius Ou SH, Shaw AT, Riely GJ. Brigatinib in Patients with Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer: A Retrospective Study. J Thorac Oncol. 2018 Jun 20. PMID: 29935304.
      View in: PubMed
    3. Schrock AB, Zhu V, Hsieh WS, Madison R, Creelan B, Silberberg J, Costin D, Bharne A, Bonta I, Bosemani T, Nikolinakos P, Ross JS, Miller VA, Ali SM, Klempner SJ, Ignatius Ou SH. Receptor Tyrosine Kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2018 Jun 05. PMID: 29883838.
      View in: PubMed
    4. Lin JJ, Zhu V, Yoda S, Yeap BY, Schrock AB, Dagogo-Jack I, Jessop NA, Jiang GY, Le LP, Gowen K, Stephens PJ, Ross JS, Ali SM, Miller VA, Johnson ML, Lovly CM, Hata AN, Gainor JF, Iafrate AJ, Shaw AT, Ou SI. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. J Clin Oncol. 2018 Apr 20; 36(12):1199-1206. PMID: 29373100.
      View in: PubMed
    5. Zhu V, Ou SI. METex14-Positive NSCLC: Time to Take the Therapy to the Target to Aim for a Cure? J Thorac Oncol. 2017 Aug; 12(8):1180-1182. PMID: 28748813.
      View in: PubMed
    6. Zhu V, Cui JJ, Fernandez-Rocha M, Schrock AB, Ali SM, Ou SI. Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib. Lung Cancer. 2017 08; 110:32-34. PMID: 28676215.
      View in: PubMed
    7. Zhu V, Hinduja S, Knezevich SR, Silveira WR, DeLozier CD. A rare case of choroid plexus carcinoma that led to the diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer). Clin Neurol Neurosurg. 2017 Jul; 158:46-48. PMID: 28460341.
      View in: PubMed
    8. Ou SI, Cui J, Schrock AB, Goldberg ME, Zhu V, Albacker L, Stephens PJ, Miller VA, Ali SM. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib. Lung Cancer. 2017 06; 108:228-231. PMID: 28625641.
      View in: PubMed
    9. Zhu V, Ou SH. Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer. Expert Opin Drug Saf. 2017 Apr; 16(4):509-514. PMID: 28276856.
      View in: PubMed
    10. Ou SI, Lee TK, Young L, Fernandez-Rocha MY, Pavlick D, Schrock AB, Zhu V, Milliken J, Ali SM, Gitlitz BJ. Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy? Lung Cancer. 2017 04; 106:110-114. PMID: 28285684.
      View in: PubMed
    11. Zhu V, Ou SI. ASCEND-2: a canary in a coal mine for descending to second-line treatment for ALK-rearranged non-small cell lung cancer. Transl Lung Cancer Res. 2016 Dec; 5(6):660-664. PMID: 28149759.
      View in: PubMed
    12. Ou SI, Young L, Schrock AB, Johnson A, Klempner SJ, Zhu V, Miller VA, Ali SM. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping. J Thorac Oncol. 2017 01; 12(1):137-140. PMID: 27666659.
      View in: PubMed
    13. Zhu V, Upadhyay D, Schrock AB, Gowen K, Ali SM, Ou SH. TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling. Lung Cancer. 2016 07; 97:48-50. PMID: 27237027.
      View in: PubMed